Adam Leitenberger joined Breastcancer.org as editorial director in 2018. He leads our editorial team and oversees content development to ensure our visitors feel informed, engaged, and supported.
Adam is an award-winning journalist and healthcare news editor, and holds an ELS certification from the Board of Editors in the Life Sciences. He has worked as a professional writer and editor since earning his master’s degree in English literature from Rutgers University in 2011.
Most recently, he served as managing editor for a physician-focused news outlet where he covered clinical research, industry news, regulatory developments, and practice trends in a number of medical specialties. There, he had the chance to connect with and learn about many patients living with chronic diseases.
“Hearing that patients regarded my team’s content as a reliable source of information has been the most rewarding aspect of my career in healthcare journalism,” Adam says. “I am so grateful for the opportunity to continue that work here at Breastcancer.org.”
Can we help guide you?
Create a profile for better recommendations
Tamoxifen (Brand Names: Nolvadex, Soltamox)
Tamoxifen is the oldest and most-prescribed selective estrogen receptor modulator (SERM)....
Breast self-exam, or regularly examining your breasts on your own, can be an important way to...
Triple-Negative Breast Cancer
Triple-negative breast cancer is cancer that tests negative for estrogen receptors, progesterone...